CelestaPro – 718613 – 11/03/2025

Recipient: CelestaPro United States Issuing Office: Center for Drug Evaluation and Research (CDER) United States Secondary Issuing Offices WARNING LETTERNovember 3, 2025CelestaPro:This is to advise you that the United States (U.S.) Food and Drug Administration (FDA)...

Glam Derma – 11/03/2025

Recipient: Glam Derma Netherlands Issuing Office: Center for Drug Evaluation and Research (CDER) United States Secondary Issuing Offices WARNING LETTERNovember 3, 2025Glam Derma:This is to advise you that the United States (U.S.) Food and Drug Administration (FDA)...

COSMO KOREA – 11/03/2025

Recipient: COSMO KOREA South Korea Issuing Office: Center for Drug Evaluation and Research (CDER) United States Secondary Issuing Offices WARNING LETTERNovember 3, 2025COSMO KOREA:This is to advise you that the United States (U.S.) Food and Drug Administration (FDA)...

Meamo – 11/03/2025

Recipient: Meamo South Korea Issuing Office: Center for Drug Evaluation and Research (CDER) United States Secondary Issuing Offices WARNING LETTERNovember 3, 2025Meamo:This is to advise you that the United States (U.S.) Food and Drug Administration (FDA) recently...

MJS Medicals – 11/03/2025

Recipient: MJS Medicals South Korea Issuing Office: Center for Drug Evaluation and Research (CDER) United States Secondary Issuing Offices WARNING LETTERNovember 3, 2025MJS Medicals:This is to advise you that the United States (U.S.) Food and Drug Administration (FDA)...

Glowface – 11/03/2025

Recipient: Glowface United States Issuing Office: Center for Drug Evaluation and Research (CDER) United States Secondary Issuing Offices WARNING LETTERNovember 3, 2025Glowface:This is to advise you that the United States (U.S.) Food and Drug Administration (FDA)...
Close